Safety of 4-valent human papillomavirus vaccine in males: a large observational post-marketing study

Kandace L Amend, Bruce Turnbull, Li Zhou, Morgan A Marks, Christine Velicer, Patricia Saddier, John D Seeger, Kandace L Amend, Bruce Turnbull, Li Zhou, Morgan A Marks, Christine Velicer, Patricia Saddier, John D Seeger

Abstract

The 4-valent human papillomavirus (HPV) vaccine (4vHPV vaccine), Gardasil®, is indicated for the prevention of several HPV-related diseases. The objective was to assess the safety of 4vHPV vaccine administered to males as part of routine care. The study used a US health insurance claims database, and included males, age 9 to 26 years, who initiated 4vHPV between October 2009 and December 2016. General safety outcomes were identified using ICD diagnosis codes associated with emergency room visits and hospitalizations in the claims database in risk periods (Days 1-60 and Days 1-14 following vaccine administration) and self-comparison periods (Days 91-150 and 91-104 for the Days 1-60 and Days 1-14 analysis, respectively). Incidence rates (IRs) and relative rates (RRs) with 95% confidence intervals (CIs) were calculated comparing the risk and self-comparison periods. In this study, 114,035 males initiated 4vHPV vaccine and received 202,737 doses. Using the 60-day time window, 5 outcomes had significantly elevated RRs after accounting for multiple comparisons: ear conditions (RR 1.28, 95% CI 1.03-1.59); otitis media and related conditions (RR 1.65, 95% CI 1.09-2.54); cellulitis and abscess of arm (RR 2.17, 95% CI 1.06-4.72); intracranial injury (RR 1.23, 95% CI 1.01-1.50); and concussion (RR 1.29, 95% CI 1.05-1.59). A higher rate of allergic reactions was noted on the day of 4vHPV vaccine receipt compared to other vaccines (21.07 events per 10,000 doses, 95% CI 18.89-23.44 versus 11.44 per 10,000 doses, 95% CI 9.84-13.22). A higher incidence rate of VTE was observed following vaccination but this association was not significant (RR 2.17, 95% CI 0.35-22.74). The 4vHPV vaccine was associated with same-day allergic reactions as well as ear infections, intracranial injury, cellulitis, and concussion within 2 months after vaccination. While allergic reaction and cellulitis are consistent with the known safety profile of 4vHPV vaccine, the association of the other outcomes were determined by an independent Safety Review Committee to be most likely a result of activities common in adolescent males that coincide with the timing of vaccination and not directly related to vaccination itself.Implications and Contributions: The study results support the general safety of routine immunization with 4vHPV vaccine among males to prevent HPV-related diseases and cancers.

Keywords: 4vhpv; human papillomavirus; human papillomavirus vaccine; vaccine safety; vaccines.

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Day 1–60 male following the dosing schedulea-c.
Figure A1.
Figure A1.
4vhpv doses by month* (2009–2016).

References

    1. de Martel C, Georges D, Bray F, Ferlay J, Clifford GM.. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180–18. doi:10.1016/S2214-109X(19)30488-7.
    1. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–70. doi:10.1002/ijc.30716.
    1. Viens LJ, Henley SJ, Watson M, Markowitz LE, Thomas CC, Thompson TD, Razzaghi H, Saraiya M. Human papillomavirus–Associated Cancers — United States, 2008–2012. MMWR Morb Mortal Wkly Rep. 2016;65(26):661–66. doi:10.15585/mmwr.mm6526a1.
    1. Tota JE, Best AF, Zumsteg ZS, Gillison ML, Rosenberg PS, Chaturvedi AK. Evolution of the oropharynx cancer epidemic in the United States: moderation of increasing incidence in younger individuals and shift in the burden to older individuals. J Clin Oncol. 2019;37(18):1538–46. doi:10.1200/JCO.19.00370.
    1. Centers for Disease Control . FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010;59:630–32. [accessed 2020 Jan 30].
    1. Food and Drug Administration . Highlights of prescribing information. Gardasil (human papillomavirus quadrivalent [types 6, 11, 16 and 18]). Silver Spring, MD: Food and Drug Administration; 2011. accessed 2020 Jan 30.
    1. Centers for Disease Control . Recommendations on the use of quadrivalent human papillomavirus vaccine in males – advisory committee on immunization practices, 2011. MMWR Morb Mortal Wkly Rep 2011;60:1705–08. [accessed 2020 Jan 30].
    1. Klein NP, Hansen J, Chao C, Velicer C, Emery M, Slezak J, Lewis N, Deosaransingh K, Sy L, Ackerson B, et al. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med. 2012;166(12):1140–48. doi:10.1001/archpediatrics.2012.1451.
    1. Gee J, Naleway A, Shui I, Baggs J, Yin R, Li R, Kulldorff M, Lewis E, Fireman B, Daley M, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the vaccine safety datalink. Vaccine. 2011;29(46):8279–84. doi:10.1016/j.vaccine.2011.08.106.
    1. Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, Izurieta HS, Ball R, Miller N, Braun M, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. Jama. 2009;302(7):750–57. doi:10.1001/jama.2009.1201.
    1. Vichnin M, Bonanni P, Klein NP, Garland SM, Block SL, Kjaer SK, Sings HL, Perez G, Haupt RM, Saah AJ, et al. An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015. Pediatr Infect Dis J. 2015;34(9):983–91. doi:10.1097/INF.0000000000000793.
    1. Stillo M, Carrillo Santisteve P, Lopalco PL. Safety of human papillomavirus vaccines: a review. Expert Opin Drug Saf. 2015;14(5):697–712. doi:10.1517/14740338.2015.1013532.
    1. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011;364(5):401–11. doi:10.1056/NEJMoa0909537.
    1. Agency for Healthcare Research and Quality . HCUP research tools and software. Healthcare Cost and Utilization Project (HCUP); 2022. [accessed 2022 April 8]. .
    1. Mehrotra DV, Heyse JF. Use of the false discovery rate for evaluating clinical safety data. Stat Methods Med Res. 2004;13(3):227–38. doi:10.1191/0962280204sm363ra.
    1. National Technical Information Service . Social security administration death master file; 2020. [accessed 2020 Jan 29]. .
    1. Centers for Disease Control. National Death Index ; 2017. [accessed 2020 Jan 29]. .
    1. ISPE . Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf. 2008;17(2):200–08. doi:10.1002/pds.1471.
    1. Amend KL, Turnbull B, Zhou L, Marks MA, Velicer C, Saddier P, Seeger JD. Vaccine initiation and 3-dose series completion of 4vhpv vaccine among US insured males 2012-2016. Vaccine. 2022;40(4):682–88. doi:10.1016/j.vaccine.2021.10.070.
    1. Centers for Disease Control . Deaths_ final data for 2016. National Vital Statistics Reports (Vol 67, No 5). 2018. Jul 26.
    1. Naleway AL, Crane B, Smith N, Daley MF, Donahue J, Gee J, Greene SK, Harrington T, Jackson LA, Klein NP, et al. Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, vaccine safety datalink, 2008-2011. Vaccine. 2016;34(1):167–71. doi:10.1016/j.vaccine.2015.10.006.
    1. Frisch M, Besson A, Clemmensen KKB, Valentiner-Branth P, Mølbak K, Hviid A. Quadrivalent human papillomavirus vaccination in boys and risk of autoimmune diseases, neurological diseases and venous thromboembolism. Int J Epidemiol. 2018;47(2):634–41. doi:10.1093/ije/dyx273.
    1. Institute of Medicine .Adverse effects of vaccines. 2011..
    1. Brotherton JM, Gold MS, Kemp AS, McIntyre PB, Burgess MA, Campbell-Lloyd S. New South wales health HPV adverse events panel. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ. 2008 Sep 9;179(6):525–33. doi:10.1503/cmaj.080916.
    1. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58(4):323–37. doi:10.1016/j.jclinepi.2004.10.012.
    1. Seeger JD. Commercial databases. In SB , editor. Pharmacoepidemiology. 5 ed. Chicester, UK: Wiley; 2012. pp. 189–208.
    1. Ferver K. The use of claims data in healthcare research. 2009. [accessed 2020 Jan 30]. .

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel